Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

MyHealthTeams

- PMLiVE

UCB presentation highlights impacts of epilepsy on daily life

The data underlines the consequences of disrupted sleep for patients and caregivers

- PMLiVE

Pistoia Alliance publishes first best-practice framework for ethical social media use in drug development

The Alliance calls for funding and expertise for the next phase of its social media project, marking its first direct engagement with oncology, rare disease and cardiology patients

- PMLiVE

UCB’s Kygevvi receives positive CHMP opinion for thymidine kinase 2 deficiency

TK2d is an extremely rare disease characterised by severe and progressive muscle weakness

- PMLiVE

UCB releases new data on Bimzelx for hidradenitis suppurativa

The disease affects around 1% of the population in most studied countries

- PMLiVE

UCB’s Fintepla shows positives results for Lennox-Gastaut syndrome

The study demonstrated a sustained reduction in seizures for patients

- PMLiVE

Minds + Assembly Launches Assembled Intelligence and Adds Stratevi to Expand Market Access and HEOR Solutions

New York, NY — 10.23.2025 — Minds + Assembly, a leading healthcare marketing firm, today announced the launch of Assembled Intelligence, an integrated communications and commercialization platform designed to unite...

BOLDSCIENCE

IPG Health logo

IPG Health expands Influencer ID marketing expertise into Europe

Strategic rollout will scale US success into key European markets, strengthening the network’s leadership of social media strategy in the health/pharma sector

IPG Health

- PMLiVE

Medical Misinformation and Sensationalism in the Age of Social Media

In today’s digital age, misinformation spreads faster than ever, often driven by sensational headlines and influencer content. These sources of misinformation often overshadow evidence-based content, creating confusion for both healthcare...

Medscape Education

- PMLiVE

UCB shares promising results for fenfluramine in ultra-rare form of epilepsy

CDKL5 deficiency disorder occurs in approximately one in 40,000 to 60,000 live births

- PMLiVE

UCB’s Bimzelx demonstrates lasting efficacy in phase 3 psoriatic arthritis trials

Approximately 125 million people worldwide are affected by some form of psoriasis

- PMLiVE

UCB’s Bimzelx granted FDA approval to treat hidradenitis suppurativa in adults

The inflammatory skin disease affects approximately one in every 100 people in the US

- PMLiVE

UCB shares ‘encouraging’ data for Alzheimer’s disease candidate bepranemab

The drug showed benefits across key secondary endpoints, including tau accumulation

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links